NADAC acquisition cost data for CLONAZEPAM 0.125 MG DIS TAB. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00555009496 | $0.7022 | 2022-06-22 | Rx |
| 49884030602 | $0.5732 | 2022-12-21 | Rx |
| 49884030652 | $0.5732 | 2022-12-21 | Rx |
| 49884030602 | $0.5732 | 2022-12-21 | Rx |
| 49884030652 | $0.5732 | 2022-12-21 | Rx |
Generic: Clonazepam | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $62.6M | 7,356,089 | 1,412,097 | $0.1515 |
| 2020 | $81.5M | 9,372,463 | 1,391,162 | $0.1549 |
| 2021 | $78.3M | 9,223,099 | 1,366,395 | $0.1522 |
| 2022 | $77.3M | 9,047,983 | 1,336,304 | $0.1542 |
| 2023 | $81.6M | 8,844,464 | 1,317,240 | $0.1684 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Florida | $6.9M | 774,950 | 128,742 |
| New York | $6.1M | 539,280 | 88,953 |
| California | $5.2M | 489,740 | 80,626 |
| Texas | $4.8M | 485,633 | 87,833 |
| Puerto Rico | $4.0M | 660,908 | 89,693 |
| Pennsylvania | $3.9M | 433,027 | 62,736 |
| Massachusetts | $3.2M | 325,798 | 43,677 |
| North Carolina | $3.2M | 346,643 | 55,215 |
| Illinois | $2.7M | 285,258 | 46,165 |
| Ohio | $2.6M | 280,582 | 41,280 |
| New Jersey | $2.6M | 236,137 | 37,997 |
| Michigan | $2.1M | 235,269 | 36,832 |
| Georgia | $2.1M | 249,832 | 41,556 |
| Missouri | $1.9M | 189,798 | 28,704 |
| Tennessee | $1.9M | 243,522 | 33,923 |
| Indiana | $1.8M | 185,432 | 28,309 |
| Alabama | $1.6M | 216,770 | 33,997 |
| Virginia | $1.6M | 173,203 | 28,328 |
| Kentucky | $1.6M | 175,852 | 24,595 |
| Wisconsin | $1.5M | 156,340 | 23,284 |
| South Carolina | $1.5M | 172,615 | 27,789 |
| Connecticut | $1.4M | 128,426 | 19,384 |
| Arkansas | $1.3M | 130,905 | 20,648 |
| Maryland | $1.2M | 114,221 | 18,810 |
| Louisiana | $1.2M | 164,361 | 25,942 |
| Minnesota | $1.2M | 113,479 | 17,229 |
| Washington | $1.1M | 115,042 | 18,335 |
| Arizona | $1.0M | 103,381 | 18,758 |
| Iowa | $853.6K | 94,826 | 13,388 |
| Colorado | $838.5K | 83,755 | 14,365 |
| Kansas | $801.7K | 80,112 | 12,330 |
| Oregon | $790.2K | 80,413 | 12,871 |
| Mississippi | $706.9K | 77,307 | 12,458 |
| Oklahoma | $637.9K | 66,439 | 10,846 |
| West Virginia | $615.2K | 77,337 | 10,590 |
| New Hampshire | $604.2K | 53,065 | 8,317 |
| Maine | $566.6K | 51,585 | 7,297 |
| Nebraska | $559.2K | 53,152 | 7,533 |
| Rhode Island | $535.9K | 58,720 | 8,422 |
| Utah | $511.4K | 56,824 | 9,336 |
| Nevada | $346.3K | 41,999 | 7,799 |
| New Mexico | $318.1K | 33,268 | 5,630 |
| Vermont | $286.4K | 24,624 | 3,533 |
| Idaho | $264.3K | 36,658 | 5,992 |
| Montana | $243.1K | 30,863 | 4,631 |
| Delaware | $242.2K | 23,510 | 4,076 |
| South Dakota | $220.4K | 26,155 | 3,616 |
| North Dakota | $191.4K | 22,065 | 3,390 |
| Hawaii | $156.0K | 13,428 | 2,459 |
| District of Columbia | $115.3K | 10,700 | 2,293 |
| Wyoming | $95.8K | 8,296 | 1,436 |
| Alaska | $71.0K | 7,107 | 1,230 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.